Therapy Areas: Central Nervous System
Biocept Expands Commercial Offering of CNSide Assay to Most Cancers that Metastasize to the Central Nervous System
17 October 2022 - - US-based molecular diagnostic assays, products, and services provider Biocept, Inc. (NASDAQ: BIOC) has launched CNSide for patients with metastatic melanoma, the company said.

Previously validated for lung, breast, and all other carcinomas, Biocept's CNSide is a proprietary CSF assay designed to better detect and inform treatment decisions for patients with metastatic cancers involving the central nervous system.

The new CNSide for melanoma assay uses a novel antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.

This assay represents a significant development in the field of neuro-oncology related diagnostics.

It is believed to be the first CLIA-validated assay designed for the quantitative identification of melanoma cells in CSF.

Melanoma is the third most common tumor type involved in CNS metastasis, with more than 60% of Stage IV melanoma patients developing CNS metastasis from their disease. Overall survival expectancy is low and patient management can be challenging due in part to diagnostic limitations.

CNSide addresses a high unmet clinical need, as current standard of care approaches--CSF cytology and MRI imaging--have limited sensitivity for detecting CNS metastasis and are not adequate to assess the response to therapy.

CNSide can also help identify molecular biomarkers considered targets for novel therapy approaches. Combined, these features help clinicians answer three key questions for patients with CNS metastasis: Is there tumor? Is there a target for treatment? Is there a trend or favorable response to treatment?

CNSide is based on Biocept's proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets.

Given the genetic changes that can occur as metastatic cancer spreads to the CNS, the evaluation of cerebrospinal fluid with CNSide provides a unique opportunity to identify biomarkers such as HER2 and EGFR in patients with metastatic carcinoma or melanoma to help guide physicians in therapy selection.

In addition, the quantitative tumor cell count assay can be used in a serial fashion to monitor the response to therapy more effectively than other current methods.

Biocept develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a range of cancers.
Login
Username:

Password: